NovoCure Limited (NVCR) Stock Analysis & AI Equity Report
NovoCure Limited (NVCR) overview
NovoCure Limited (NVCR) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 655m and operating profit of USD -154m; the year-end share price was 12.93 USD and market capitalisation was USD 1,455m. NovoCure Limited is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get NovoCure Limited's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About NovoCure Limited
NovoCure develops and markets medical devices that deliver Tumor Treating Fields, electric fields used as cancer therapy. Its commercial products include Optune Gio for glioblastoma, Optune Lua for metastatic non-small cell lung cancer and pleural mesothelioma, and Optune Pax for locally advanced pancreatic cancer. The company serves patients and healthcare providers in multiple countries.
Generate the NovoCure Limited report
NovoCure Limited is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for NovoCure Limited and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on NovoCure Limited
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.